Drug-controlled systems and uses thereof

Patent metadata

Field	Value
Publication number	US-11660288-B2
Application number	US-202117462185-A
Country	US
Kind code	B2
Filing date	Aug 31, 2021
Priority date	Aug 31, 2020
Publication date	May 30, 2023
Grant date	May 30, 2023

Abstract

The technology described herein is directed to polypeptide systems using drug-controlled peptide docking domains and cognate docking domain-binding peptides and their use to control cellular signaling, activity, and/or gene expression.

First claim

What is claimed herein is:

1. A polypeptide comprising, from N-terminus to C-terminus:
i) a drug-controlled peptide docking domain, wherein the drug-controlled peptide docking domain is hepatitis C virus (HCV) nonstructural protein 3 (NS3);
ii) a cognate docking domain-binding peptide comprising medium affinity CP5-46A-4D5E (PMED) or high affinity CP5-46-4D5E (P HI ); and
iii) a recombinase comprising at least one decreased cooperativity mutation, wherein the recombinase comprising at least one decreased cooperativity mutation is Cre R32M or Cre R32V .

Assignees

• Univ Boston

Inventors

• Ngo John T
• Dunlop Mary
• Tague Elliot Parker
• Tague Nathan Michael
• Marzilli Alexander Michael

Classifications

• C07K14/47

  from mammals · CPC title

• C07K2319/70

  containing domain for protein-protein interaction · CPC title

• C07K2319/80

  containing a DNA binding domain, e.g. Lacl or Tet-repressor · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K31/5377

  not condensed and containing further heterocyclic rings, e.g. timolol · CPC title